Thomas J George

Thomas J George, M.D., F.A.C.P.

Professor

Department: MD-HEMATOLOGY/ONCOLOGY
Business Phone: (352) 273-7832
Business Email: tgeorge@ufl.edu

About Thomas J George

Dr. George is a clinical investigator and educator with a focus on gastrointestinal malignancies. As director of the GI Oncology Program at the University of Florida, Dr. George helps to oversee the treatment of all patients with GI malignancies. He previously served as chair of the Medical Advisory Board to the State of Florida Department of Health and the Screen for Life Colorectal Cancer Screening Program, which targets historically underserved populations. He also recently completed a 10 year term as the gubernatorial-appointed chair of the Florida Cancer Control and Research Advisory Council, which advises the legislature, Department of Health, and state surgeon general on all cancer related matters and policy. He currently serves as the Associate Director for Clinical Research at the UF Health Cancer Center. Through participation with large oncology clinical trial cooperative groups and the National Cancer Institute, Dr. George is an active clinician and clinical investigator in GI malignancies and early phase clinical trials testing new therapies for patients with advanced cancers. He is a member of the medical honor society Alpha Omega Alpha, the American Society of Clinical Oncology, and numerous cancer research groups.

Additional Positions:
Associate Director for Clinical Research
2016 – Current · UF Health Cancer Center
Director, Experimental Therapeutics and GI Oncology Programs
2014 – Current · UF Health Cancer Center
Related Links:

Accomplishments

University of Florida Term Professor Award
2018-2019 · University of Florida
Exemplary Mentor Award
2017 · University of Florida
Master Clinician
2013 · UF Department of Medicine
Most Valuable Player Award
2013 · UF Health Cancer Center
Exemplary Teacher
2011 · University of Florida
Excellence in Research Award
2010 · University of Florida
Exemplary Teacher
2010 · University of Florida
Excellence in Teaching (Resident/Fellows)
2009 · University of Florida
Excellence in Research Award
2008 · University of Florida
Exemplary Teacher
2008 · University of Florida
Excellence in Teaching (Fellows)
2007 · University of Florida
Excellence in Teaching (Medical Students)
2007 · University of Florida
Fellow
2007 · American College of Physicians

Teaching Profile

Courses Taught
2017-2023
GMS6847 Translational Research and Therapeutics: Bench, Bedside, Community, & Policy
2019
PHA6136 Clinical Applications of Precision Medicine: Oncology
2018
MDC7200 Medicine Clerkship
2018
MDC7203 Senior Medicine Clerk
2018
BME7980 Research for Doctoral Dissertation
2021
PHA6935 Selected Topics in Pharmacy

Board Certifications

  • Hematology
    American Board of Internal Medicine
  • Internal Medicine
    American Board of Internal Medicine
  • Oncology
    American Board of Internal Medicine

Clinical Profile

Specialties
  • Hematology and Oncology
  • Oncology
Areas of Interest
  • Cancer treatment information
  • Colon cancer screening
  • Colorectal cancer
  • Colorectal cancer – resources
  • Esophageal cancer
  • Liver metastases
  • Pancreatic cancer
  • Stomach cancer

Research Profile

Clinical research in gastrointestinal malignancies is a primary aspect of Dr. George’s academic interests.  Specific areas of focus include active participation and development of clinical trials to promote novel drug application in patient care, quality of life/cancer care decision making, and identification of predictive markers for individualized therapy.  He has been a 10 year Gubernatorial appointee to the Executive Committee and immediate past Chair of the Florida Cancer Control and Research and Advisory Council which advises the legislature on matters related to cancer care and research in the state. He is a dedicated mentor and teacher of fellows, residents, and students in the College of Medicine and junior faculty both at UF and other major institutions.

Experimental Therapeutics – Dr. George is involved as a Principle Investigator in numerous clinical trials aimed at determining the optimal treatment for patients with gastrointestinal malignancies and bringing new therapies to patients with advanced cancers.  Collaboration includes numerous national clinical trial groups as well as the National Cancer Institute.  Representative protocols include studies in colon, rectal, pancreatic, esophagogastric, hepatobiliary and other treatment refractory cancers.  These novel therapies offer patients access to new treatments and hold the promise of becoming the next breakthrough in cancer patient care. 

Personalized Oncology – As cancer care becomes more complex, focus on a tailored approach to individualized treatments which maximize benefit while minimizing risk is critical.  Research involving the identification of specific markers or elements of a patient or their cancer which will predict, in advance, response to a given therapy is an area of active investigation.  The incorporation of new molecular markers, gene expression profiling, and pharmacogenomics into clinical care will help to provide patients with truly personalized care. 

Quality of Life and Decision Making – Patients and their loved ones facing the new diagnosis of a cancer face a variety of potentially overwhelming treatment options and decisions.  Collaboration with behavioral scientists, communication experts, and others are helping to break down the complex process of decision making in an attempt to determine how best to deliver treatment options and maximize quality of life.

Mentoring the Next Generation of Oncologists – The next generation holds the keys to continuing the work currently ongoing in cancer biology, therapeutics, and patient care.  Cancer therapies and knowledge are constantly changing and medicine requires a lifelong commitment to education. Development of novel educational tools, training modules, advanced curricula, mentorship and sponsorship aimed at providing oncologists with the skills needed to practice state of the art medicine while maintaining the humanism and sensitivity required for being entrusted with the honor of caring for patients with cancer is an area of ongoing professional and research interest.

Areas of Interest
  • Clinical Trials Design & Analysis
  • Cancer
  • Cancer Genetics
  • Cancer Immunotherapy
  • Cancer Informatics
  • Cancer Therapeutics
  • Clinical Trial Interventions
  • Immuno-Oncology
  • Interventional oncology
Open Researcher and Contributor ID (ORCID)

0000-0002-6249-9180

Publications

2022
A Subjective Culture Approach to Cancer Prevention: Rural Black and White Adults’ Perceptions of Using Virtual Health Assistants to Promote Colorectal Cancer Screening
Health Communication. 37(9):1123-1134 [DOI] 10.1080/10410236.2021.1910166.
2022
Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update
Journal of Clinical Oncology. 40(8):892-910 [DOI] 10.1200/jco.21.02538.
2022
Administration of Immune Checkpoint Inhibitors Near the End of Life
JCO Oncology Practice. 18(6):e849-e856 [DOI] 10.1200/op.21.00689.
2022
Association of social determinants of health with late diagnosis and survival of patients with pancreatic cancer.
Journal of gastrointestinal oncology. 13(3):1204-1214 [DOI] 10.21037/jgo-21-788. [PMID] 35837201.
2022
Associations of Overall Survival with Geriatric Nutritional Risk Index in Patients with Advanced Pancreatic Cancer
Nutrients. 14(18) [DOI] 10.3390/nu14183800. [PMID] 36145174.
2022
Clinical Updates for Colon Cancer Care in 2022.
Clinical colorectal cancer. 21(3):198-203 [DOI] 10.1016/j.clcc.2022.05.006. [PMID] 35729033.
2022
Communicating risk to promote colorectal cancer screening: a multi-method study to test tailored versus targeted message strategies
Health Education Research. 37(2):79-93 [DOI] 10.1093/her/cyac002. [PMID] 35234890.
2022
Creating and Implementing a Principal Investigator Tool Kit for Enhancing Accrual to Late Phase Clinical Trials: Development and Usability Study
JMIR Cancer. 8(3) [DOI] 10.2196/38514. [PMID] 36006678.
2022
Do they speak like me? Exploring how perceptions of linguistic difference may influence patient perceptions of healthcare providers
Medical Education Online. 27(1) [DOI] 10.1080/10872981.2022.2107470. [PMID] 35912473.
2022
Eligibility Criteria Perpetuate Disparities in Enrollment and Participation of Black Patients in Pancreatic Cancer Clinical Trials
Journal of Clinical Oncology. 40(20):2193-2202 [DOI] 10.1200/jco.21.02492.
2022
Emergence of ocular toxicities associated with novel anticancer therapeutics: What the oncologist needs to know.
Cancer treatment reviews. 105 [DOI] 10.1016/j.ctrv.2022.102376. [PMID] 35303547.
2022
Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers
JCO Precision Oncology. (6) [DOI] 10.1200/po.21.00245.
2022
Longitudinal Study of Circulating Biomarkers in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Biosensors. 12(4) [DOI] 10.3390/bios12040206. [PMID] 35448266.
2022
Osteopenia is associated with wasting in pancreatic adenocarcinoma and predicts survival after surgery
Cancer Medicine. 11(1):50-60 [DOI] 10.1002/cam4.4416. [PMID] 34791809.
2022
Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials
JNCI: Journal of the National Cancer Institute. 114(1):60-67 [DOI] 10.1093/jnci/djab187. [PMID] 34505880.
2022
Simulating Colorectal Cancer Trials Using Real-World Data
JCO Clinical Cancer Informatics. (6) [DOI] 10.1200/cci.21.00195.
2022
Telehealth and racial disparities in colorectal cancer screening: A pilot study of how virtual clinician characteristics influence screening intentions.
Journal of clinical and translational science. 6(1) [DOI] 10.1017/cts.2022.386. [PMID] 35619640.
2022
Using Circulating Tumor DNA for Colon Cancer Adjuvant Therapy: To Be or Not to Be?
Clinical Cancer Research. 28(3):438-440 [DOI] 10.1158/1078-0432.ccr-21-3564.
2021
A Comprehensive Review of Randomized Clinical Trials Shaping the Landscape of Rectal Cancer Therapy
Clinical Colorectal Cancer. 20(1):1-19 [DOI] 10.1016/j.clcc.2020.07.009.
2021
A Pilot Study Examining the Efficacy of Delivering Colorectal Cancer Screening Messages via Virtual Health Assistants.
American journal of preventive medicine. 61(2):251-255 [DOI] 10.1016/j.amepre.2021.01.014. [PMID] 33888362.
2021
Activity of Sorafenib Plus Capecitabine in Previously Treated Metastatic Colorectal Cancer.
The oncologist. 26(5):362-e724 [DOI] 10.1002/onco.13689. [PMID] 33512054.
2021
Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database
JNCI: Journal of the National Cancer Institute. 113(12):1693-1704 [DOI] 10.1093/jnci/djab123. [PMID] 34405233.
2021
Development of a Credible Virtual Clinician Promoting Colorectal Cancer Screening via Telehealth Apps for and by Black Men: Qualitative Study
JMIR Formative Research. 5(12) [DOI] 10.2196/28709. [PMID] 34780346.
2021
Exploring the feasibility of using real-world data from a large clinical data research network to simulate clinical trials of Alzheimer’s disease
npj Digital Medicine. 4(1) [DOI] 10.1038/s41746-021-00452-1. [PMID] 33990663.
2021
Extracting social determinants of health from electronic health records using natural language processing: a systematic review
Journal of the American Medical Informatics Association. 28(12):2716-2727 [DOI] 10.1093/jamia/ocab170. [PMID] 34613399.
2021
Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance)
Cancer Epidemiology Biomarkers & Prevention. 30(2):404-411 [DOI] 10.1158/1055-9965.epi-20-1274.
2021
Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance)
Cancer Epidemiology, Biomarkers & Prevention. 30(2):404-411 [DOI] 10.1158/1055-9965.epi-20-1274.
2021
Immunotherapy Management in Special Cancer Patient Populations
JCO Oncology Practice. 17(5):240-245 [DOI] 10.1200/op.20.00996.
2021
Key changes to improve social presence of a virtual health assistant promoting colorectal cancer screening informed by a technology acceptance model.
BMC medical informatics and decision making. 21(1) [DOI] 10.1186/s12911-021-01549-z. [PMID] 34158046.
2021
Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study
Clinical Cancer Research. 27(6):1612-1622 [DOI] 10.1158/1078-0432.ccr-20-1831.
2021
New onset of type 2 diabetes as a complication after cancer diagnosis: A systematic review
Cancer Medicine. 10(2):439-446 [DOI] 10.1002/cam4.3666. [PMID] 33355998.
2021
Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma
The Oncologist. 26(10):825-e1674 [DOI] 10.1002/onco.13853. [PMID] 34101295.
2021
Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database
JNCI: Journal of the National Cancer Institute. 113(4):400-407 [DOI] 10.1093/jnci/djaa124. [PMID] 32835356.
2021
Systematic Analysis of Extracting Data on Advance Directives from Patient Electronic Health Records (EHR) in Terminal Oncology Patients.
Journal of palliative care. 36(4):211-218 [DOI] 10.1177/08258597211001153. [PMID] 33711237.
2021
The association between cognitive impairment and breast and colorectal cancer screening utilization.
BMC cancer. 21(1) [DOI] 10.1186/s12885-021-08321-6. [PMID] 33975576.
2021
The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pancreatic Cancer
Cancers. 13(4) [DOI] 10.3390/cancers13040809. [PMID] 33671939.
2021
Utility of Restaging MRI Following Neoadjuvant Chemoradiotherapy for Stage II-III Rectal Adenocarcinoma.
Cureus. 13(10) [DOI] 10.7759/cureus.19037. [PMID] 34858737.
2021
Validation of Real-World Data-based Endpoint Measures of Cancer Treatment Outcomes.
AMIA … Annual Symposium proceedings. AMIA Symposium. 2021:716-725 [PMID] 35308944.
2020
A Pilot Study Determining Comprehension and the Acceptability of a Cancer Research Study Website for Cancer Patients and Caregivers.
Journal of cancer education : the official journal of the American Association for Cancer Education. 35(3):589-598 [DOI] 10.1007/s13187-019-01501-w. [PMID] 30847837.
2020
Assessing the effect of data integration on predictive ability of cancer survival models.
Health informatics journal. 26(1):8-20 [DOI] 10.1177/1460458218824692. [PMID] 30672356.
2020
Assessing the practice of data quality evaluation in a national clinical data research network through a systematic scoping review in the era of real-world data
Journal of the American Medical Informatics Association. 27(12):1999-2010 [DOI] 10.1093/jamia/ocaa245. [PMID] 33166397.
2020
Clinical Trial Generalizability Assessment in the Big Data Era: A Review
Clinical and Translational Science. 13(4):675-684 [DOI] 10.1111/cts.12764. [PMID] 32058639.
2020
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
Nature Reviews Clinical Oncology. 17(12):757-770 [DOI] 10.1038/s41571-020-0392-0. [PMID] 32632268.
2020
Differential response to targeted acupuncture by gender in patients with gastrointestinal cancer cachexia: secondary analysis of a randomized controlled trial.
Acupuncture in medicine : journal of the British Medical Acupuncture Society. 38(1):53-60 [DOI] 10.1177/0964528419873670. [PMID] 31544469.
2020
Disparities in Pancreatic Ductal Adenocarcinoma—The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes
Cancer Medicine. 9(12):4069-4082 [DOI] 10.1002/cam4.3042. [PMID] 32285629.
2020
Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer
Clinical Gastroenterology and Hepatology. 18(12):2717-2723.e3 [DOI] 10.1016/j.cgh.2019.11.046. [PMID] 31811950.
2020
How to Transition from Single-Gene Pharmacogenetic Testing to Preemptive Panel-Based Testing: A Tutorial.
Clinical pharmacology and therapeutics. 108(3):557-565 [DOI] 10.1002/cpt.1912. [PMID] 32460360.
2020
Incorporation of lateral microfiltration with immunoaffinity for enhancing the capture efficiency of rare cells.
Scientific reports. 10(1) [DOI] 10.1038/s41598-020-71041-7. [PMID] 32848184.
2020
International Classification of Diseases, Tenth Revision, Clinical Modification social determinants of health codes are poorly used in electronic health records.
Medicine. 99(52) [DOI] 10.1097/MD.0000000000023818. [PMID] 33350768.
2020
Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study
Clinical Cancer Research. [DOI] 10.1158/1078-0432.ccr-20-1831.
2020
Quantitative Analysis of Oncology Professional Learning Preferences.
JCO oncology practice. 16(2):e155-e165 [DOI] 10.1200/JOP.18.00731. [PMID] 32045553.
2020
Tailoring virtual human‐delivered interventions: A digital intervention promoting colorectal cancer screening for Black women
Psycho-Oncology. 29(12):2048-2056 [DOI] 10.1002/pon.5538. [PMID] 32893399.
2020
Using Real-World Data to Rationalize Clinical Trials Eligibility Criteria Design: A Case Study of Alzheimer’s Disease Trials.
AMIA … Annual Symposium proceedings. AMIA Symposium. 2020:717-726 [PMID] 33936446.
2019
5-FU induced cardiotoxicity: case series and review of the literature.
Cardio-oncology (London, England). 5 [DOI] 10.1186/s40959-019-0048-3. [PMID] 32154019.
2019
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors
Oncology. 97(2):102-111 [DOI] 10.1159/000500571.
2019
Assessing the Validity of a a priori Patient-Trial Generalizability Score using Real-world Data from a Large Clinical Data Research Network: A Colorectal Cancer Clinical Trial Case Study.
AMIA … Annual Symposium proceedings. AMIA Symposium. 2019:1101-1110 [PMID] 32308907.
2019
Augmentation of Cancer Cachexia Components With Targeted Acupuncture in Patients With Gastrointestinal Cancers: A Randomized Controlled Pilot Study
Integrative Cancer Therapies. 18 [DOI] 10.1177/1534735418823269. [PMID] 30791747.
2019
Creating an mHealth App for Colorectal Cancer Screening: User-Centered Design Approach
JMIR Human Factors. 6(2) [DOI] 10.2196/12700. [PMID] 31066688.
2019
Facilitation or Hindrance: Physicians’ Perception on Best Practice Alerts (BPA) Usage in an Electronic Health Record System.
Health communication. 34(9):942-948 [DOI] 10.1080/10410236.2018.1443263. [PMID] 29485296.
2019
Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches
JNCI: Journal of the National Cancer Institute. 111(11):1131-1141 [DOI] 10.1093/jnci/djz093. [PMID] 31322663.
2019
Innenrücktitelbild: Integration of Lateral Filter Arrays with Immunoaffinity for Circulating‐Tumor‐Cell Isolation (Angew. Chem. 23/2019)
Angewandte Chemie. 131(23):7961-7961 [DOI] 10.1002/ange.201904831.
2019
Inside Back Cover: Integration of Lateral Filter Arrays with Immunoaffinity for Circulating‐Tumor‐Cell Isolation (Angew. Chem. Int. Ed. 23/2019)
Angewandte Chemie International Edition. 58(23):7879-7879 [DOI] 10.1002/anie.201904831.
2019
Integration of Lateral Filter Arrays with Immunoaffinity for Circulating‐Tumor‐Cell Isolation
Angewandte Chemie. 131(23):7688-7692 [DOI] 10.1002/ange.201901412.
2019
Integration of Lateral Filter Arrays with Immunoaffinity for Circulating‐Tumor‐Cell Isolation
Angewandte Chemie International Edition. 58(23):7606-7610 [DOI] 10.1002/anie.201901412. [PMID] 30958635.
2019
Microfluidic Isolation of Circulating Tumor Cells and Cancer Stem-Like Cells from Patients with Pancreatic Ductal Adenocarcinoma.
Theranostics. 9(5):1417-1425 [DOI] 10.7150/thno.28745. [PMID] 30867841.
2019
National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer
Cancer. [DOI] 10.1002/cncr.32150. [PMID] 31017664.
2019
Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal.
Current oncology (Toronto, Ont.). 26(4):e515-e521 [DOI] 10.3747/co.26.4311. [PMID] 31548820.
2019
Pancreas Cancer-Associated Weight Loss
Oncologist. 24(5):691-701 [DOI] 10.1634/theoncologist.2018-0266. [PMID] 30591550.
2019
Predicting unintentional weight loss in patients with gastrointestinal cancer.
Journal of cachexia, sarcopenia and muscle. 10(3):526-535 [DOI] 10.1002/jcsm.12398. [PMID] 30834673.
2019
Racial and ethnic disparities in a state‐wide registry of patients with pancreatic cancer and an exploratory investigation of cancer cachexia as a contributor to observed inequities
Cancer Medicine. 8(6):3314-3324 [DOI] 10.1002/cam4.2180. [PMID] 31074202.
2019
Rural-urban disparities in tobacco retail access in the southeastern United States: CVS vs. the dollar stores.
Preventive medicine reports. 15 [DOI] 10.1016/j.pmedr.2019.100935. [PMID] 31360628.
2019
The Influence of Patient Identification and Narrative Transportation on Intentions to Participate in Cancer Research.
Journal of cancer education : the official journal of the American Association for Cancer Education. 34(4):725-734 [DOI] 10.1007/s13187-018-1364-2. [PMID] 29721780.
2019
The Proteome of Pancreatic Cancer-Derived Exosomes Reveals Signatures Rich in Key Signaling Pathways.
Proteomics. 19(13) [DOI] 10.1002/pmic.201800394. [PMID] 31070281.
2019
Thermal ablation versus wedge or segmental resection in patients with early stage hepatocellular carcinoma: a population survival analysis.
HPB : the official journal of the International Hepato Pancreato Biliary Association. 21(2):249-257 [DOI] 10.1016/j.hpb.2018.07.004. [PMID] 30057124.
2019
Tobacco and E-cigarette use among cancer survivors in the United States.
PloS one. 14(12) [DOI] 10.1371/journal.pone.0226110. [PMID] 31815948.
2019
Two Cases of Rare Pancreatic Malignancies.
Journal of pancreatic cancer. 5(1):26-33 [DOI] 10.1089/pancan.2019.0007. [PMID] 31338486.
2019
Using photography to explore psychological distress in patients with pancreatic cancer and their caregivers: a qualitative study.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 27(1):321-328 [DOI] 10.1007/s00520-018-4330-y. [PMID] 29959574.
2018
A Phase Ib Study of Ruxolitinib Plus Gemcitabine +/- Nab-Paclitaxel in Patients With Advanced Solid Tumors
Oncotargets and Therapy. 11:2399-2407 [DOI] 10.2147/OTT.S157331. [PMID] 29750040.
2018
An ontology-guided semantic data integration framework to support integrative data analysis of cancer survival.
BMC medical informatics and decision making. 18(Suppl 2) [DOI] 10.1186/s12911-018-0636-4. [PMID] 30066664.
2018
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.
Journal of gastrointestinal oncology. 9(4):610-617 [DOI] 10.21037/jgo.2018.05.06. [PMID] 30151257.
2018
Body composition changes differ by gender in stomach, colorectal, and biliary cancer patients with cachexia: Results from a pilot study.
Cancer medicine. 7(8):3695-3703 [DOI] 10.1002/cam4.1665. [PMID] 29971962.
2018
Clinical Factors as a Component of the Personalized Treatment Approach to Advanced Pancreatic Cancer: a Systematic Literature Review.
Journal of gastrointestinal cancer. 49(1):1-8 [DOI] 10.1007/s12029-017-0021-z. [PMID] 29110227.
2018
Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial.
Contemporary clinical trials. 68:7-13 [DOI] 10.1016/j.cct.2018.03.001. [PMID] 29535047.
2018
Extragastrointestinal stromal tumors of the pelvic cavity and the vagina: Two case reports and review of the literature.
Gynecologic oncology reports. 25:3-7 [DOI] 10.1016/j.gore.2018.04.006. [PMID] 30140724.
2018
Non-surgical management of patients with intrahepatic cholangiocarcinoma in the United States, 2004-2015: an NCDB analysis.
Journal of gastrointestinal oncology. 9(3):536-545 [DOI] 10.21037/jgo.2018.02.04. [PMID] 29998019.
2018
Objective Preoperative Parameters Predict Difficult Pelvic Dissections and Clinical Outcomes.
The Journal of surgical research. 232:15-25 [DOI] 10.1016/j.jss.2018.05.042. [PMID] 30463711.
2018
Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203).
Cancer. 124(4):688-697 [DOI] 10.1002/cncr.30967. [PMID] 29211295.
2018
Prognostic Value of Clinical vs Pathologic Stage in Rectal Cancer Patients Receiving Neoadjuvant Therapy.
Journal of the National Cancer Institute. 110(5):460-466 [DOI] 10.1093/jnci/djx228. [PMID] 29165692.
2018
Providers’ Perceptions of Barriers to Optimal Communication With Patients During the Postcolonoscopy Experience.
Journal of patient experience. 5(4):272-278 [DOI] 10.1177/2374373518759548. [PMID] 30574547.
2018
Rectal cancer patients younger than 50 years lack a survival benefit from NCCN guideline-directed treatment for stage II and III disease.
Cancer. 124(17):3510-3519 [DOI] 10.1002/cncr.31527. [PMID] 29984547.
2018
Rural-urban and racial-ethnic differences in awareness of direct-to-consumer genetic testing.
BMC public health. 18(1) [DOI] 10.1186/s12889-018-5190-6. [PMID] 29471813.
2018
Total Neoadjuvant Therapy: A Shifting Paradigm in Locally Advanced Rectal Cancer Management.
Clinical colorectal cancer. 17(1):1-12 [DOI] 10.1016/j.clcc.2017.06.008. [PMID] 28803718.
2017
A clinically applicable muscular index predicts long-term survival in resectable pancreatic cancer.
Surgery. 161(4):930-938 [DOI] 10.1016/j.surg.2016.09.038. [PMID] 27932030.
2017
A Novel Microfluidic Device for Isolation of Circulating Tumor Cells from Pancreatic Cancer Blood Samples.
Methods in molecular biology (Clifton, N.J.). 1634:33-53 [DOI] 10.1007/978-1-4939-7144-2_3. [PMID] 28819839.
2017
Analysis of the Cost Effectiveness of Laparoscopic Pancreatoduodenectomy.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 21(9):1404-1410 [DOI] 10.1007/s11605-017-3466-2. [PMID] 28567575.
2017
Cancer Survivor’s History and Physical.
Southern medical journal. 110(1):37-44 [DOI] 10.14423/SMJ.0000000000000585. [PMID] 28052173.
2017
Data Integration through Ontology-Based Data Access to Support Integrative Data Analysis: A Case Study of Cancer Survival.
Proceedings. IEEE International Conference on Bioinformatics and Biomedicine. 2017:1300-1303 [DOI] 10.1109/BIBM.2017.8217849. [PMID] 29707415.
2017
Explore Care Pathways of Colorectal Cancer Patients with Social Network Analysis.
Studies in health technology and informatics. 245 [PMID] 29295355.
2017
Human Pancreatic Cancer Cells Induce a MyD88-Dependent Stromal Response to Promote a Tumor-Tolerant Immune Microenvironment.
Cancer research. 77(3):672-683 [DOI] 10.1158/0008-5472.CAN-16-1765. [PMID] 27864347.
2017
Human pancreatic cancer xenografts recapitulate key aspects of cancer cachexia.
Oncotarget. 8(1):1177-1189 [DOI] 10.18632/oncotarget.13593. [PMID] 27901481.
2017
Influential factors on treatment decision making among patients with colorectal cancer: A scoping review.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 25(9):2943-2951 [DOI] 10.1007/s00520-017-3763-z. [PMID] 28589309.
2017
Infusion Room-Based Transition to Practice Model for Teaching Cancer Systemic Therapy Management.
Journal of oncology practice. 13(11):e909-e915 [DOI] 10.1200/JOP.2017.023549. [PMID] 28885879.
2017
Innovation or Inconsistency? Framing Colorectal Cancer Guidelines to Improve Public Perceptions of Updated Screening Recommendations
Journal of Language and Social Psychology. 36(1, SI):14-27 [DOI] 10.1177/0261927X16663258.
2017
Management of Malignant Bowel Obstruction Associated With GI Cancers.
Journal of oncology practice. 13(7):426-434 [DOI] 10.1200/JOP.2017.022210. [PMID] 28697317.
2017
Neoadjuvant transarterial radiation lobectomy for colorectal hepatic metastases: a small cohort analysis on safety, efficacy, and radiopathologic correlation.
Journal of gastrointestinal oncology. 8(3):E43-E51 [DOI] 10.21037/jgo.2017.01.26. [PMID] 28736649.
2017
NSC30049 inhibits Chk1 pathway in 5-FU-resistant CRC bulk and stem cell populations.
Oncotarget. 8(34):57246-57264 [DOI] 10.18632/oncotarget.19778. [PMID] 28915668.
2017
Orthotopic Patient-Derived Pancreatic Cancer Xenografts Engraft Into the Pancreatic Parenchyma, Metastasize, and Induce Muscle Wasting to Recapitulate the Human Disease.
Pancreas. 46(6):813-819 [DOI] 10.1097/MPA.0000000000000843. [PMID] 28609371.
2017
Randomized Clinical Trials in Colon and Rectal Cancer.
Surgical oncology clinics of North America. 26(4):689-704 [DOI] 10.1016/j.soc.2017.05.008. [PMID] 28923225.
2017
Sociodemographic Factors Associated With Stage of Diagnosis and Treatment Uptake Among Patients With Colorectal Cancer: a Brief Report
Journal of Cancer Policy. 12:79-82 [DOI] 10.1016/j.jcpo.2017.03.001.
2017
Stereotactic body radiation therapy for oligoprogression of metastatic disease from gastrointestinal cancers: A novel approach to extend chemotherapy efficacy.
Oncology letters. 13(3):1087-1094 [DOI] 10.3892/ol.2016.5540. [PMID] 28454218.
2017
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.
Cancer chemotherapy and pharmacology. 80(4):861-867 [DOI] 10.1007/s00280-017-3401-y. [PMID] 28756516.
2017
The Multidisciplinary Approach to Localized Pancreatic Adenocarcinoma.
Current treatment options in oncology. 18(12) [DOI] 10.1007/s11864-017-0515-8. [PMID] 29143898.
2016
“It is just another test they want to do”: Patient and caregiver understanding of the colonoscopy procedure.
Patient education and counseling. 99(4):651-658 [DOI] 10.1016/j.pec.2015.10.021. [PMID] 26597383.
2016
Barriers to a Career Focus in Cancer Prevention: A Report and Initial Recommendations From the American Society of Clinical Oncology Cancer Prevention Workforce Pipeline Work Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(2):186-93 [DOI] 10.1200/JCO.2015.63.5979. [PMID] 26527778.
2016
Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer.
The oncologist. 21(11):1306-1314 [DOI] 10.1634/theoncologist.2016-0148. [PMID] 27682134.
2016
Cancer Hallmark-Based Gene Sets and Personalized Medicine for Patients With Stage II Colon Cancer.
JAMA oncology. 2(1):23-4 [DOI] 10.1001/jamaoncol.2015.3614. [PMID] 26501743.
2016
Clinical, morphologic, and immunophenotypic characteristics of ampullary carcinomas with an emphasis on SMAD4 expression.
Journal of gastrointestinal oncology. 7(6):974-981 [DOI] 10.21037/jgo.2016.06.14. [PMID] 28078121.
2016
Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma.
Journal of gastrointestinal oncology. 7(2):173-80 [DOI] 10.3978/j.issn.2078-6891.2015.071. [PMID] 27034783.
2016
EGFR family and cMet expression profiles and prognostic significance in esophagogastric adenocarcinoma.
Journal of gastrointestinal oncology. 7(6):838-847 [DOI] 10.21037/jgo.2016.06.09. [PMID] 28078108.
2016
Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture.
The American journal of pathology. 186(6):1537-46 [DOI] 10.1016/j.ajpath.2016.02.009. [PMID] 27102771.
2016
It’s Tough to Make Predictions, Especially About the Future … of Rectal Cancer.
Oncology (Williston Park, N.Y.). 30(6):563-4 [PMID] 27306710.
2016
Nicotine Reduces Survival via Augmentation of Paracrine HGF-MET Signaling in the Pancreatic Cancer Microenvironment.
Clinical cancer research : an official journal of the American Association for Cancer Research. 22(7):1787-99 [DOI] 10.1158/1078-0432.CCR-15-1256. [PMID] 26667487.
2016
NRG GI002: Moving the needle toward TNT in locally advanced rectal cancer.
Bulletin of the American College of Surgeons. 101(10):61-2 [PMID] 28937723.
2016
Oncologic and Perioperative Outcomes Following Selective Application of Laparoscopic Pancreaticoduodenectomy for Periampullary Malignancies.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 20(7):1343-9 [DOI] 10.1007/s11605-016-3136-9. [PMID] 27142633.
2016
Standardization of surgical care in a high-volume center improves survival in resected pancreatic head cancer.
American journal of surgery. 212(2):195-201.e1 [DOI] 10.1016/j.amjsurg.2016.03.001. [PMID] 27260793.
2016
Use of Electronic Cigarettes Among Cancer Survivors in the U.S.
American journal of preventive medicine. 51(5):762-766 [DOI] 10.1016/j.amepre.2016.04.015. [PMID] 27242079.
2015
A Metastatic Colon Adenocarcinoma Harboring Braf V600E Has A Durable Major Response To Dabrafenib/Trametinib And Chemotherapy.
Oncotargets and Therapy. 8:3561-4 [DOI] 10.2147/OTT.S90766. [PMID] 26664139.
2015
Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer.
Cancer immunology, immunotherapy : CII. 64(12):1553-63 [DOI] 10.1007/s00262-015-1760-y. [PMID] 26423423.
2015
Durable Clinical Benefit To Trastuzumab And Chemotherapy In A Patient With Metastatic Colon Adenocarcinoma Harboring Erbb2 Amplification.
Oncoscience. 2(6):581-4 [DOI] 10.18632/oncoscience.175. [PMID] 26244165.
2015
Interobserver Variability Of Mitotic Index And Utility Of Phh3 For Risk Stratification In Gastrointestinal Stromal Tumors.
American Journal of Clinical Pathology. 143(3):385-92 [DOI] 10.1309/AJCPAPH28VHZEKNQ. [PMID] 25696796.
2015
Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer.
Cancer medicine. 4(8):1224-39 [DOI] 10.1002/cam4.444. [PMID] 25766842.
2015
Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials.
Current colorectal cancer reports. 11(5):275-280 [PMID] 26321890.
2015
Pathways to colonoscopy in the South: seeds of health disparities.
American journal of public health. 105(4):e103-11 [DOI] 10.2105/AJPH.2014.302347. [PMID] 25713952.
2015
Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma.
Molecular cancer therapeutics. 14(1):80-9 [DOI] 10.1158/1535-7163.MCT-14-0229. [PMID] 25344582.
2015
The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival.
BMC cancer. 15 [DOI] 10.1186/s12885-015-1820-x. [PMID] 26498838.
2014
“Tissue is the issue”: circulating tumor cells in pancreatic cancer.
Journal of gastrointestinal cancer. 45 Suppl 1(0 1):222-5 [DOI] 10.1007/s12029-014-9638-3. [PMID] 25012516.
2014
A new predictive molecular marker for cetuximab benefit in rectal cancer?
Journal of the National Cancer Institute. 106(7) [DOI] 10.1093/jnci/dju154. [PMID] 24957075.
2014
Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip.
Lab on a chip. 14(1):89-98 [DOI] 10.1039/c3lc51017d. [PMID] 24220648.
2014
Comparison of C-Met Immunoreactivity in Surgically Treated Gastroesophageal Adenocarcinoma Using Two Commercially Available Antibodies
Laboratory Investigation. 94(1)
2014
Effects of Patient and Caregiver Literacy On Preference for Physician-Led Medical Decisions
Psycho-Oncology. 23(1, SI)
2014
Feasibility/Acceptability of Quality of Life Research Among Distressed Individuals Affected By Pancreatic Cancer
Psycho-Oncology. 23(1, SI)
2014
Fellowship engagement in hematology/oncology professionalism training.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 32(11):1164-6 [DOI] 10.1200/JCO.2013.54.6879. [PMID] 24590646.
2014
Phase 1/2 Study of Krn330, a Fully Human Anti-A33 Monoclonal Antibody, Plus Irinotecan as Second-Line Treatment for Patients With Metastatic Colorectal Cancer
Investigational New Drugs. 32(4):682-690 [DOI] 10.1007/s10637-014-0088-3. [PMID] 24691674.
2014
Src Inhibition Is Still a Relevant Target in Pancreatic Cancer
Oncologist. 19(2) [DOI] 10.1634/theoncologist.2013-0410. [PMID] 24457377.
2013
Argininosuccinate Synthase as a Novel Biomarker for Inflammatory Conditions
Biomarkers. 18(3):242-249 [DOI] 10.3109/1354750X.2013.773080. [PMID] 23510167.
2013
Characteristics and outcomes of adenosquamous carcinoma of the pancreas.
Gastrointestinal cancer research : GCR. 6(3):75-9 [PMID] 23936547.
2013
Opportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy
Journal of the National Cancer Institute. 105(10):686-693 [DOI] 10.1093/jnci/djt055. [PMID] 23503600.
2013
Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity.
Acta oncologica (Stockholm, Sweden). 52(3):498-505 [DOI] 10.3109/0284186X.2012.762997. [PMID] 23477361.
2013
Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma.
Oncology reports. 29(4):1259-67 [DOI] 10.3892/or.2013.2290. [PMID] 23426976.
2012
Proton Therapy for Pancreatic Cancer – Toxicity Data and Early Outcomes
Pancreas. 41
2011
Klatskin Tumor- Clinical Outcome and Prognostic Factors
Higher Education Policy. 54
2011
Multiagent regimens for metastatic colorectal cancer: if some is good, more must be better.
Journal of the National Cancer Institute. 103(1):4-5 [DOI] 10.1093/jnci/djq483. [PMID] 21123834.
2011
Protocol information provides opportunity for patient safety and quality improvement.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(18) [DOI] 10.1200/JCO.2011.36.3200. [PMID] 21576645.
2011
Squamous cell carcinoma of the anal margin: the university of Florida experience.
American journal of clinical oncology. 34(4):406-10 [DOI] 10.1097/COC.0b013e3181e9c0c0. [PMID] 20881476.
2011
The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma.
Alimentary pharmacology & therapeutics. 34(2):205-13 [DOI] 10.1111/j.1365-2036.2011.04697.x. [PMID] 21605146.
2010
A phase II trial of neoadjuvant capecitabine combined with hyperfractionated accelerated radiation therapy in locally advanced rectal cancer.
American journal of clinical oncology. 33(3):251-6 [DOI] 10.1097/COC.0b013e3181a650e8. [PMID] 19823074.
2010
Adequacy of published oncology randomized controlled trials to provide therapeutic details needed for clinical application.
Journal of the National Cancer Institute. 102(10):702-5 [DOI] 10.1093/jnci/djq117. [PMID] 20410466.
2010
Adjuvant high-dose interferon-{alpha} for resected melanoma in a patient with HIV infection.
The oncologist. 15(7):695-8 [DOI] 10.1634/theoncologist.2009-0335. [PMID] 20555019.
2010
Definitive radiotherapy for squamous cell carcinoma of the anal canal.
American journal of clinical oncology. 33(1):47-51 [DOI] 10.1097/COC.0b013e31819e2be2. [PMID] 19704368.
2010
Gastroduodenal ulcerations as a delayed complication of hepatic metastasis radioembolization.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(35):e735-6 [DOI] 10.1200/JCO.2010.29.5782. [PMID] 20823407.
2010
Hepatitis B reactivation and rituximab in the oncology practice.
The oncologist. 15(10):1113-21 [DOI] 10.1634/theoncologist.2010-0106. [PMID] 20930099.
2010
Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment.
The journal of supportive oncology. 8(2):72-7 [PMID] 20464886.
2009
Impact of a Simple Intervention That Improves Colon Cancer Lymph Node Yield and Assessement
Journal of Clinical Oncology. 27
2009
Impact of An Annual Hematology/Oncology Fellow Wet Laboratory Program On Fund of Biomedical Knowledge
Blood. 114
2009
Pancreatic heterotopia masquerading as duodenal carcinoid.
Gastrointestinal cancer research : GCR. 3(3):118-20 [PMID] 19626155.
2009
Radiotherapy in the treatment of resectable rectal adenocarcinoma.
American journal of clinical oncology. 32(6):629-38 [DOI] 10.1097/COC.0b013e31817ff8e4. [PMID] 19593081.
2008
Adjuvant radiotherapy for cutaneous melanoma.
Cancer. 112(6):1189-96 [DOI] 10.1002/cncr.23306. [PMID] 18260153.
2007
Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature.
The oncologist. 12(11):1332-5 [PMID] 18055853.
2006
Anesthetic Properties Of A Propofol Microemulsion In Dogs.
Anesthesia and Analgesia. 103(4):882-7 [DOI] 10.1213/01.ane.0000237126.57445.80. [PMID] 17000798.
2006
Factors associated with parameters of engraftment potential of umbilical cord blood.
Transfusion. 46(10):1803-12 [PMID] 17002638.
2006
Rationale and appropriate use of chemotherapy and radiotherapy for pancreatic ductal adenocarcinoma.
Current gastroenterology reports. 8(2):111-20 [PMID] 16533473.
. [DOI] 10.53354/pc.gr.151114.
Barriers and facilitators of obtaining SDoH of patients with cancer through the EHR using natural language processing technology: A qualitative study (Preprint)
. [DOI] 10.2196/preprints.43059.
Creating an mHealth App for Colorectal Cancer Screening: User-Centered Design Approach (Preprint)
. [DOI] 10.2196/preprints.12700.
Development of a Credible Virtual Clinician Promoting Colorectal Cancer Screening via Telehealth Apps for and by Black Men: Qualitative Study (Preprint)
. [DOI] 10.2196/preprints.28709.

Grants

Nov 2022 ACTIVE
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study of IO-202 in Combination With Pembrolizumab in Subjects With Advanced, Relapsed, or Refractory Solid Tumors
Role: Principal Investigator
Funding: ERGOMED PLC via IMMUNE-ONC THERAPEUTICS
Sep 2022 ACTIVE
First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects with Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS viral oncogene homolog (NRAS) Mutated Solid Tumors
Role: Principal Investigator
Funding: SYNEOS HEALTH via ELICIO THERAPEUTICS
Sep 2022 ACTIVE
Precision Clinical Trial Recruitment to Promote Cancer Health Equity Across Florida
Role: Co-Investigator
Funding: NATL INST OF HLTH NCI
Aug 2022 – Sep 2022
A Phase Ib open label study to assess the safety and pharmacokinetics of NUC-3373, a nucleotide analogue, given in combination with standard agents used in colorectal cancer treatment
Role: Principal Investigator
Funding: NUCANA
Aug 2022 ACTIVE
AN OPEN-LABEL, MULTICENTER, PHASE I STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF RO7444973 IN PARTICIPANTS WITH UNRESECTABLE AND/OR METASTATIC MAGE-A4-POSITIVE SOLID TUMORS
Role: Principal Investigator
Funding: GENENTECH INC
May 2022 ACTIVE
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
Role: Principal Investigator
Funding: MEDPACE via NOVITA PHARMACEUTICALS
Mar 2022 ACTIVE
A Screening Protocol to Support Preliminary Eligibility for Clinical Trials Evaluating Safety and Efficacy of Adoptive Cell Therapies in Participants with Solid Tumors and Hematologic Malignancies
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC via GLAXO SMITHKLINE
Mar 2022 ACTIVE
NRG Oncology Network Group Operations Center
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL via NATL INST OF HLTH NCI
Feb 2022 ACTIVE
CORRECT-MRD II: SECOND COLORECTAL CANCER CLINICAL VALIDATION STUDY TO PREDICT RECURRENCE USING A CIRCULATING TUMOR DNA ASSAY TO DETECT MINIMAL RESIDUAL DISEASE
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL via EXACT SCIENCES CORPORATION
Jan 2022 ACTIVE
Appendix F to the Precision Promise Master Protocol: Canakinumab and Spartalizumab in Combination with Nab-Paclitaxel and Gemcitabine in Subjects with Metastatic Pancreatic Cancer
Role: Principal Investigator
Funding: LABCORP DRUG DEVELOPMENT via NOVARTIS PHARMACEUTICALS CORP
Jan 2022 ACTIVE
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
Role: Principal Investigator
Funding: SEAGEN
Jan 2022 ACTIVE
MicroRNA turnover induced by target RNAs in Colorectal Cancer
Role: Co-Investigator
Funding: AMER CANCER SOC
Oct 2021 ACTIVE
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors
Role: Principal Investigator
Funding: MERCK AND COMPANY INC
Oct 2021 ACTIVE
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study
Role: Principal Investigator
Funding: ONCOC4
Oct 2021 ACTIVE
Intestinal Microbiota Associations with Toxicity and Outcomes in Patients with Pancreatic Cancer during Neoadjuvant Curative Treatment
Role: Other
Funding: BRISTOL-MYERS SQUIBB FOUNDATION
Sep 2021 ACTIVE
A Study of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers
Role: Principal Investigator
Funding: BRISTOL MYERS SQUIBB CO
Aug 2021 – Mar 2022
ASCO-ACCC Pilot Project to Increase Racial and Ethnic Diversity in Clinical Trials
Role: Principal Investigator
Funding: AMER SOC FOR CLINICAL ONCOLOGY
Aug 2021 ACTIVE
CTOA
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Jul 2021 ACTIVE
McJunkin Family Foundation – UFHCC
Role: Co-Investigator
Funding: UF FOUNDATION via MCJUNKIN FAMILY FOUNDATION
Jun 2021 ACTIVE
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Role: Principal Investigator
Funding: AMER SOC FOR CLINICAL ONCOLOGY
Jun 2021 ACTIVE
Phase 1/2 First-in-Human (FIH) Study of Leukocyte Immunoglobulin- Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies
Role: Principal Investigator
Funding: IQVIA BIOTECH via JOUNCE THERAPEUTICS
May 2021 ACTIVE
Appendix E to the Precision Promise Master Protocol Pamrevlumab in Combination with Gemcitabone/NAB-Paclitaxel in Subjects With Metastatic Pancreatic Cancer
Role: Principal Investigator
Funding: LABCORP DRUG DEVELOPMENT via FIBROGEN INC
Apr 2021 ACTIVE
Optimizing the Population Representativeness of Older Adults in Cancer Trials
Role: Co-Investigator
Funding: NATL INST OF HLTH NCI
Mar 2021 – Feb 2022
NRG Oncology Network Group Operations Center
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL via NATL INST OF HLTH NCI
Feb 2021 ACTIVE
A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
Role: Principal Investigator
Funding: CMED CLINICAL SERVICES via BIOMED VALLEY DISCOVERIES
Feb 2021 ACTIVE
TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL
Role: Principal Investigator
Funding: SYNEOS HEALTH via GENENTECH INC
Oct 2020 – Jun 2022
A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)
Role: Principal Investigator
Funding: MERCK SHARP & DOHME
Jul 2020 – Aug 2021
BrafPanc: A Phase II Trial of Binimetinib in combination with Encorafenib in patients with Pancreatic Malignancies and a somatic BRAFV600E mutation
Role: Principal Investigator
Funding: MAYO CLINIC via ARRAY BIOPHARMA INC
Jul 2020 – Jan 2022
An open-label, Phase 1, first-in-human, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics and tumor response profile of the ILDR2 function-blocking antibody BAY 1905254 in patients with advanced solid tumors
Role: Principal Investigator
Funding: BAYER HEALTHCARE PHARMACEUTICALS
Jul 2020 ACTIVE
Colorectal cancer (CRC)
Role: Principal Investigator
Funding: UF FOUNDATION via MCJUNKIN FAMILY FOUNDATION
Jun 2020 ACTIVE
A Phase 1b Study of ASP1951, a GITR Agonistic Antibody, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Role: Principal Investigator
Funding: SYNEOS HEALTH via ASTELLAS PHARMA US, INC
Jun 2020 ACTIVE
A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Na?ve Metastatic Pancreatic Cancer (GIANT)
Role: Project Manager
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH NCI
Jun 2020 – May 2021
Pancreatic Cancer Action Network Precision Promise Clinical Trial Consortium Sites
Role: Principal Investigator
Funding: Pancreatic Cancer Action Network
Mar 2020 ACTIVE
VICKtOrY Early Clinical Trials Consortium
Role: Principal Investigator
Funding: YALE UNIV via NATL INST OF HLTH NCI
Mar 2020 – Feb 2021
NRG Oncology Network Group Operations Center
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL via NATL INST OF HLTH NCI
Jan 2020 ACTIVE
Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
Jan 2020 ACTIVE
Precision Promise Platform Trial For Metastatic Pancreatic Cancer
Role: Principal Investigator
Funding: LABCORP DRUG DEVELOPMENT via Pancreatic Cancer Action Network
Jan 2020 ACTIVE
Extracting information from clinical narratives for Clinical Outcomes Research
Role: Co-Investigator
Funding: PATIENT-CENTERED OUTCOMES RES INST
Jan 2020 ACTIVE
The benefits and harms of lung cancer screening in Florida
Role: Project Manager
Funding: NATL INST OF HLTH NCI
Dec 2019 ACTIVE
Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH NCI
Nov 2019 ACTIVE
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer
Role: Principal Investigator
Funding: MERCK SHARP & DOHME
Sep 2019 ACTIVE
Testing novel drug combination for pancreatic cancer
Role: Co-Project Director/Principal Investigator
Funding: FL DEPT OF HLTH BIOMED RES PGM/J&E KING
Aug 2019 ACTIVE
MATCH/EAY131
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
Aug 2019 ACTIVE
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation
Role: Principal Investigator
Funding: AMGEN INC
Aug 2019 ACTIVE
A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO? (Telotristat Ethyl) plus First-line Chemotherapy in Patients with Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC)
Role: Principal Investigator
Funding: PPD DEVELOPMENT via TERSERA THERAPEUTICS
May 2019 – Oct 2021
Collaboration Research Agreement
Role: Principal Investigator
Funding: MEDIMMUNE
Mar 2019 ACTIVE
A Phase IB Study of Pembrolizumab in Combination with Pemetrexed and Oxaliplatin in Patients with Chemo-refractory Metastatic Colorectal Cancer
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL
Mar 2019 ACTIVE
A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH NCI
Mar 2019 ACTIVE
A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH
Mar 2019 ACTIVE
Molecular Analysis for Therapy Choice (MATCH)
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH NCI
Mar 2019 ACTIVE
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH NCI
Mar 2019 ACTIVE
RANDOMIZED DOUBLE-BLIND PHASE III TRIAL OF VITAMIN D3 SUPPLEMENTATION IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (SOLARIS)
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH NCI
Mar 2019 ACTIVE
NRG Oncology Network Group Operations Center
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH NCI
Mar 2019 – Feb 2020
NRG Oncology Network Group Operations Center
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL via NATL INST OF HLTH NCI
Mar 2019 – Feb 2020
FDP Research Subaward Agreement- Amendment 1
Role: Principal Investigator
Funding: UNIV OF PITTSBURGH via NATL INST OF HLTH NCI
Jan 2019 ACTIVE
Systematic Analysis of Clinical Study Generalizability Assessment Methods with Informatics
Role: Co-Investigator
Funding: FL STATE UNIV via NATL INST OF HLTH NIA
Oct 2018 ACTIVE
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
Role: Principal Investigator
Funding: DRUGDEV INC via INCYTE CORPORATION
Sep 2018 – Feb 2019
ET-CTN with Phase 2 Emphasis
Role: Principal Investigator
Funding: UNIV OF PITTSBURGH via NATL INST OF HLTH NCI
Jul 2018 ACTIVE
A Phase II Study Evaluating the Combination of Neratinib Plus Trastuzumab or Neratinib Plus Cetuximab in Patients with "Quadruple Wild-Type" KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Based on HER2 Status: Amplified, Non-Amplified (Wild-Type) or Mutated
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL
Jun 2018 ACTIVE
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Role: Principal Investigator
Funding: SEAGEN
Apr 2018 ACTIVE
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Nal-IRI in Combination with 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal-IRI Study)
Role: Principal Investigator
Funding: IPSEN BIOPHARMACEUTICALS
Mar 2018 ACTIVE
A Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and other DNA Damage Response (DDR) Pathway Deficient Neoplasms
Role: Principal Investigator
Funding: TESARO INC
Mar 2018 – Apr 2021
Phase 1a/1b Dose Escalation And Expansion Study Of Sbp-101 In Combination With Nab-Paclitaxel and Gemcitabine In Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Role: Principal Investigator
Funding: SUN BIOPHARMA
Mar 2018 – Feb 2019
Integrated Translational Genoproteomics Center at Washington University
Role: Principal Investigator
Funding: WASHINGTON UNIV SAINT LOUIS via NATL INST OF HLTH NCI
Feb 2018 – Apr 2022
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
Jan 2018 ACTIVE
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH NCI
Jan 2018 – Oct 2021
A Phase 1 Study of NLG802 for Adult Patients with Recurrent Advanced Solid Tumors
Role: Principal Investigator
Funding: NEW LINK GENETICS
Jan 2018 – May 2022
A Phase II Study to Assess the Activity of PD-L Inhibition with Durvalumab (MEDI4736) after Chemo-Radiotherapy in Patients with Stage II-IV Microsatellite Stable (MSS) Rectal Cancer
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL
Jan 2018 ACTIVE
Training Program for Applied Research and Development in Genomic Medicine
Role: Other
Funding: NATL INST OF HLTH NHGRI
Aug 2017 – Aug 2022
Long Term Follow-Up Study for Subjects Previously Treated with Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy
Role: Principal Investigator
Funding: NEW LINK GENETICS
Aug 2017 – Aug 2022
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Role: Principal Investigator
Funding: INCYTE BIOSCIENCES INT SARL
May 2017 – Sep 2021
A Phase II Study of the Dual Immune Checkpoint Blockade With Durvalumab (MEDI4736) Plus Tremelimumab Following Palliative Hypofractionated Radiation in Patients With Microsatellite Stable (MSS) Metastatic Colorectal Cancer Progressing on Chemotherapy
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL
Mar 2017 – May 2022
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy
Role: Principal Investigator
Funding: INCYTE CORPORATION
Mar 2017 – Feb 2019
NRG Oncology Network Group Operations Center – NRG-GI002
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH
Mar 2017 – Feb 2018
Integrated Translational Genoproteomics Center at Washington University
Role: Principal Investigator
Funding: WASHINGTON UNIV SAINT LOUIS via NATL INST OF HLTH NCI
Feb 2017 – Jan 2022
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Gastric Cancer (FRACTION-Gastric Cancer)
Role: Principal Investigator
Funding: BRISTOL MYERS SQUIBB CO
Feb 2017 – Nov 2021
A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination with MEDI4736 in Adult Subjects with Select Advanced Solid Tumors
Role: Principal Investigator
Funding: ICON CLINICAL RESEARCH INC via MEDIMMUNE
Feb 2017 ACTIVE
A patient-centered intervention using virtual technology to reduce colorectal cancer disparities in primary care
Role: Co-Investigator
Funding: NATL INST OF HLTH NCI
Jan 2017 – Jan 2022
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH NCI
Jan 2017 ACTIVE
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH NCI
Dec 2016 – Jun 2020
F020991 – Colorectal Cancer Screening Project
Role: Principal Investigator
Funding: UF FOUNDATION via MCJUNKIN FAMILY FOUNDATION
Oct 2016 – Feb 2019
NRG Affiliate Master-Federal
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH NCI
Jul 2016 – Jun 2017
Leading Innovation for Transformation (LIFT) Organized Approaches to Colorectal Cancer Screening FY17
Role: Co-Investigator
Funding: FL DEPT OF HLTH via CTRS FOR DISEASE CONTROL AND PREVENTION
Jun 2016 – Jun 2021
214 Fund – Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo plus Cisplatin and Gemcitabine as First-Line Treatment in Patients with Advanced or Metastatic Biliary Tract Cancer
Role: Principal Investigator
Funding: ELI LILLY AND CO
Jun 2016 – May 2019
214 Fund A Phase 1, open-label study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment
Role: Principal Investigator
Funding: TAIHO ONCOLOGY INC
May 2016 – May 2021
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients with Stage III Colon Cancer (ARGO)
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL
May 2016 – May 2021
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients with Stage III Colon Cancer (ARGO)
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL
Apr 2016 – Apr 2020
A MULTI-CENTER STUDY OF THE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR, IBRUTINIB, IN COMBINATION WITH MEDI4736…
Role: Principal Investigator
Funding: Pharmacyclics, Incorporated
Mar 2016 – Feb 2019
INTEGRATED TRANSLATIONAL GENOPROTEOMICS CENTER AT WASHINGTON UNIVERSITY
Role: Principal Investigator
Funding: WASHINGTON UNIV SAINT LOUIS via NATL INST OF HLTH
Mar 2016 – Feb 2019
NRG Oncology network group operations center
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH NCI
Mar 2016 – Feb 2019
NRG Oncology Network Group Operations Center
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL via NATL INST OF HLTH NCI
Jan 2016 ACTIVE
214 Fund – A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
Role: Principal Investigator
Funding: MERCK SHARP & DOHME
Dec 2015 – Jan 2020
miscellaneous donors
Role: Principal Investigator
Funding: MISCELLANEOUS DONORS
Oct 2015 ACTIVE
NSABP Foundation Subcontract
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL
Oct 2015 – Feb 2016
NRG Oncology Network Group Operations Center
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL via NATL INST OF HLTH
Apr 2015 – Jun 2016
A Multi-Center Study of the Brutons Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with MEDI4736, in Subjects with Relapsed or Refractory Solid Tumors
Role: Principal Investigator
Funding: Pharmacyclics, Incorporated
Mar 2015 – Feb 2019
Molecular Analysis for Therapy Choice (MATCH)
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH NCI
Feb 2015 – Feb 2018
293An Open-Label Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to or Failing Chemotherapy
Role: Principal Investigator
Funding: TAIHO PHARMACEUTICAL
Feb 2015 ACTIVE
UF Health Cancer Center Pilot Project Grants funded through the Florida Consortium of National Cancer Institute Centers Program
Role: Project Manager
Funding: UF HEALTH SHANDS HOSPITAL
Feb 2015 – Jan 2020
UF Health Cancer Center Collaborative Cancer Related Seed Grant funded through the Florida Consortium of National Cancer Institute Centers Program
Role: Project Manager
Funding: UF HEALTH SHANDS HOSPITAL
Sep 2014 – Aug 2019
Florida Minority Cancer Research and Training Center: Feasibility Studies
Role: Co-Investigator
Funding: NATL INST OF HLTH NCI
Sep 2014 – Feb 2019
A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH NCI
Jul 2014 – Jul 2017
Single Agent Adjuvant Aflibercept (ziv-Aflibercept) for Patients with Resected or Ablated Metastatic Colorectal Cancer: A Randomized Phase II Study
Role: Principal Investigator
Funding: LIFESPAN RHODE ISLAND HOSPITAL
Jun 2014 ACTIVE
A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY OF NAB-PACLITAXEL PLUS GEMCITABINE VERSUS GEMCITABINE ALONE…
Role: Principal Investigator
Funding: CELGENE CORP
Jun 2014 – Jun 2017
A Phase 3, Multicenter, Open-label, Randomized Study of nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma
Role: Principal Investigator
Funding: CELGENE CORP
May 2014 – May 2018
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Role: Principal Investigator
Funding: SOUTHWEST ONCOLOGY GROUP
Apr 2014 – Aug 2018
A phase III trial of 6 versus 12 treatments of adjuvant FOLFOX plus celecoxib or placebo for patients with resected stage III colon cancer
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL via NATL INST OF HLTH
Mar 2014 – Feb 2019
Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
Jan 2014 – Jan 2019
A PHASE III STUDY OF CHEMOTHERAPY WITH OR WITHOUT ALGENPANTUCEL-L (HYPERACUTE-PANCREAS) IMMUNOTHERAPY IN …..
Role: Principal Investigator
Funding: NEW LINK GENETICS
Jan 2014 – Jan 2017
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute?-Pancreas) Immunotherapy in Subjects with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Role: Principal Investigator
Funding: NEW LINK GENETICS
Aug 2013 – Aug 2018
OPERATING ACCOUNT MEDICINE HEM/ONC
Role: Principal Investigator
Funding: UNIV OF FLORIDA
May 2013 – May 2017
A Phase IB Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Role: Principal Investigator
Funding: INCYTE CORPORATION
Feb 2013 ACTIVE
NSABP Patient Registry and Biospecimen Profiling Repository
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL
Feb 2013 – Feb 2020
NSABP Patient Registry and Biospecimen Profiling Repository
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL
Jan 2013 ACTIVE
Determination of predictive biomarker for dasatinib use in combination with Chemotherapy in advanced pancreatic cancer
Role: Principal Investigator
Funding: BRISTOL MYERS SQUIBB CO
Nov 2012 ACTIVE
PHASE II STUDY OF 5-FLUOROURACIL, OXALIPLATIN PLUS DASATINIB(FOLFOX-D) IN FIRST-LINE ADVANCED/METASTATIC PANCREATIC
Role: Principal Investigator
Funding: BRISTOL MYERS SQUIBB CO
Nov 2012 – Nov 2017
Phase II study of 5-fluorouracil, oxaliplatin plus dasatinib (FOLFOX-D) in first-line metastatic pancreatic adenocarcinoma
Role: Principal Investigator
Funding: BRISTOL MYERS SQUIBB CO
Jul 2012 – Jul 2020
A Pase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Prepoperative Combined Modaligy Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL via NATL INST OF HLTH NCI
Aug 2011 – Feb 2021
Sorafenib plus Capecitabine (SorCape) in previously treated metastatic colorectal cancer
Role: Principal Investigator
Funding: BAYER HEALTHCARE PHARMACEUTICALS
Jan 2011 – Jun 2017
A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute?-Pancreatic Cancer Vaccine in Subjects with Surgically Resected Pancreatic Cancer
Role: Principal Investigator
Funding: NEW LINK GENETICS
Nov 2008 – Nov 2017
A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil with or without Oxaliplatin in the Treatment of Patients with
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL via NATL INST OF HLTH
Jul 2007 – Aug 2016
Clinical and Translational Science Institute
Role: Project Manager
Funding: UF RESEARCH FOU
Dec 2002 – Dec 2017
(ACOSOG) Z9001: PHASE III RNDMZD DOUBLE-BLIND STUDY OF ADJUVANT ST1571 (GLEEVER TM) VS PLACEBO IN PATIENTS FOLLOWING THE
Role: Principal Investigator
Funding: DUKE UNIVERSITY via NATL INST OF HLTH

Education

Fellowship – Hematology and Oncology
2005 · University of Florida
Residency – Internal Medicine
2001 · University of Florida
Internship – Internal Medicine
1999 · University of Florida
Doctor of Medicine w/ Honors
1998 · University of Florida
Bachelor of Science w/ Highest Honors
1994 · University of Florida

Contact Details

Phones:
Business:
(352) 273-7832
Emails:
Business:
tgeorge@ufl.edu
Addresses:
Business Mailing:
PO Box 100278
GAINESVILLE FL 32610
Business Street:
PO Box 100278
GAINESVILLE FL 32610